Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Navidea Biopharmaceuticals Inc (NY: NAVB )

N/A UNCHANGED
Last Price Updated: 8:00 PM EDT, Oct 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Navidea Biopharmaceuticals Inc

< Previous 1 2 3 4 5 6 Next >
Earnings Scheduled For August 11, 2021
Companies Reporting Before The Bell • Wireless Telecom Group (AMEX:WTT) is likely to report earnings for its second quarter. • Gamida Cell (NASDAQ:GMDA) is... 
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
Navidea Biopharmaceuticals to Host Second Quarter 2021 Earnings Conference Call and Business Update
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For May 11, 2021
Companies Reporting Before The Bell • Oxford Lane Capital (NASDAQ:OXLC) is estimated to report earnings for its fourth quarter. • ReWalk Robotics (NASDAQ:RWLK) is... 
Via Benzinga
Navidea Biopharmaceuticals Announces First 110 Subjects Imaged in NAV3-35 Normative Database Phase 2b Study to Support Rheumatoid Arthritis Indications
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Navidea Stock Gains After FDA Grants End Of Phase 2 Meeting To Discuss Rheumatoid Arthritis Program
The FDA has granted Navidea Biopharmaceuticals Inc's (NYSE: NAVB) request for an End-of-Phase 2 Type B meeting to discuss its ongoing program in... 
Via Benzinga
Exposures Product Safety
Navidea Biopharmaceuticals Announces End-of-Phase 2 Type B Meeting Request Granted by the FDA to Discuss Ongoing Clinical Program in Rheumatoid Arthritis
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Macrophage Therapeutics, Inc. Wins Delaware Case Against Michael Goldberg for Breach of Fiduciary Duty
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Navidea Biopharmaceuticals Announces Issuance of U.S. Patent for Diagnosis and Treatment of Viral Infections
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Navidea Biopharmaceuticals Reports First Quarter 2021 Financial Results
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Navidea Biopharmaceuticals Announces NIH Grant Award to UC San Diego for Clinical Study Evaluating Tc99m Tilmanocept as a Kidney Imaging Agent
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV) -... 
Via Benzinga
Exposures COVID-19 Product Safety
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... 
Via Benzinga
Exposures COVID-19 Product Safety
Navidea Biopharmaceuticals Announces Changes to Board of Directors Composition
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Navidea Biopharmaceuticals to Host First Quarter 2021 Earnings Conference Call and Corporate Update
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
Navidea Biopharmaceuticals Announces Acceptance of Therapeutics Focused Abstract for Presentation at the Frontiers in Cancer Immunotherapy Symposium
From Navidea Biopharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.